Hager Investment Management Services LLC Buys 940 Shares of IDEXX Laboratories, Inc. $IDXX

Hager Investment Management Services LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 213.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,381 shares of the company’s stock after buying an additional 940 shares during the period. Hager Investment Management Services LLC’s holdings in IDEXX Laboratories were worth $882,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. WealthCollab LLC bought a new stake in IDEXX Laboratories during the second quarter valued at approximately $30,000. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $31,000. Armstrong Advisory Group Inc. raised its holdings in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the period. Salomon & Ludwin LLC purchased a new position in IDEXX Laboratories during the third quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in IDEXX Laboratories during the third quarter valued at $35,000. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. JPMorgan Chase & Co. increased their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Piper Sandler decreased their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. UBS Group lowered their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Finally, Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $783.33.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director directly owned 648 shares in the company, valued at $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 18,180 shares of company stock valued at $11,626,996. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 1.3%

Shares of IDXX opened at $657.38 on Thursday. The business’s 50 day moving average is $674.55 and its 200 day moving average is $668.99. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a market capitalization of $52.34 billion, a PE ratio of 50.30, a price-to-earnings-growth ratio of 3.94 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the business earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.